Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Descriptive study of the residual anti-pneumococcal immunity in patients with Anti-neutrophil
 cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who have previously gone through
 pneumococcal immunization.
The purpose of this study is to determine, through serotype-specific enzyme linked
 immunosorbent assay (ELISA) and opsonophagocytosis (OPA) titres whether AAV patients who have
 gone through pneumococcal vaccination are protected against invasive pneumococcal diseases
 (IPD).
Inclusion Criteria:

 -  Age ≥ 18 years

 -  Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: diagnosis for
 granulomatosis with polyangiitis, microscopic polyangiitis or eosinophilic
 granulomatosis with polyangiitis according to American College of Rheumatology
 criteria

 -  Anti-pneumococcal immunization in the past 36 months

 -  History of anti-pneumococcal vaccination according to French recommendations (simple
 vaccine schedule with PPV23 or combine vaccine schedule with PCV13 followed by PPV23 8
 weeks later)

 Exclusion Criteria:

 -  Known or suspected pregnancy

 -  Splenectomy

 -  Patient without social security coverage

 -  Patient opposal